Jounce Therapeutics Current Cash

Jounce Therapeutics (JNCE) currently reports a current cash of $150M as of December 2022. That compares with $96M in the prior-year period — up 57.6% year over year. Use the charts on this page to explore Jounce Therapeutics's current cash history and peer comparisons.

Jounce Therapeutics's current cash increased from $96M to $150M — a 57.6% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Jounce Therapeutics reported $150M in current cash as of December 2022. That compares with $96M in the prior-year period — up 57.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Jounce Therapeutics, and consider following JNCE for alerts when major investors trade the stock.

Jounce Therapeutics is classified in the Healthcare sector. On current cash, it currently shows $150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing JNCE with unrelated industries.